Two‐Year Trajectories of DIAL2 ‐Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL ‐ STEP Study
Year: 2026
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.71534
Authors: Antonio Maria Labate, Provvidenza Villari
Institution: Azienda Socio Sanitaria Territoriale del Garda
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7225634569